751 related articles for article (PubMed ID: 18028247)
1. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness.
Stapleton JA; Watson L; Spirling LI; Smith R; Milbrandt A; Ratcliffe M; Sutherland G
Addiction; 2008 Jan; 103(1):146-54. PubMed ID: 18028247
[TBL] [Abstract][Full Text] [Related]
2. Combination treatment with varenicline and nicotine replacement therapy.
Ebbert JO; Burke MV; Hays JT; Hurt RD
Nicotine Tob Res; 2009 May; 11(5):572-6. PubMed ID: 19351781
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and abstinence outcomes among tobacco quitline enrollees using varenicline or nicotine replacement therapy.
Biazzo LL; Froshaug DB; Harwell TS; Beck HN; Haugland C; Campbell SL; Helgerson SD
Nicotine Tob Res; 2010 Jun; 12(6):567-73. PubMed ID: 20378640
[TBL] [Abstract][Full Text] [Related]
4. Flexible and extended dosing of nicotine replacement therapy or varenicline in comparison to fixed dose nicotine replacement therapy for smoking cessation: rationale, methods and participant characteristics of the FLEX trial.
Tulloch H; Pipe A; Els C; Aitken D; Clyde M; Corran B; Reid RD
Contemp Clin Trials; 2014 Jul; 38(2):304-13. PubMed ID: 24861558
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of selectors of nicotine replacement therapy.
Shiffman S; Di Marino ME; Sweeney CT
Tob Control; 2005 Oct; 14(5):346-55. PubMed ID: 16183986
[TBL] [Abstract][Full Text] [Related]
6. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
[TBL] [Abstract][Full Text] [Related]
7. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline.
Foulds J
Int J Clin Pract; 2006 May; 60(5):571-6. PubMed ID: 16700857
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
Oncken C; Gonzales D; Nides M; Rennard S; Watsky E; Billing CB; Anziano R; Reeves K
Arch Intern Med; 2006 Aug 14-28; 166(15):1571-7. PubMed ID: 16908789
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of varenicline for smoking cessation.
Hays JT; Ebbert JO; Sood A
Am J Med; 2008 Apr; 121(4 Suppl 1):S32-42. PubMed ID: 18342165
[TBL] [Abstract][Full Text] [Related]
11. Treatment of nicotine dependence with Chantix (varenicline).
Rankin KV; Jones DL
Tex Dent J; 2011 May; 128(5):457-61. PubMed ID: 21834368
[TBL] [Abstract][Full Text] [Related]
12. Varenicline for smoking cessation: a placebo-controlled, randomized study.
Wang C; Xiao D; Chan KP; Pothirat C; Garza D; Davies S
Respirology; 2009 Apr; 14(3):384-92. PubMed ID: 19192221
[TBL] [Abstract][Full Text] [Related]
13. Effect of nicotine lozenges on affective smoking withdrawal symptoms: secondary analysis of a randomized, double-blind, placebo-controlled clinical trial.
Shiffman S
Clin Ther; 2008 Aug; 30(8):1461-75. PubMed ID: 18803988
[TBL] [Abstract][Full Text] [Related]
14. Reduced affective symptoms during tobacco dependence treatment with varenicline.
Grosshans M; Mutschler J; Hermann D; Mann K; Diehl A
Addiction; 2009 May; 104(5):859-61. PubMed ID: 19413797
[TBL] [Abstract][Full Text] [Related]
15. Varenicline in the management of smoking cessation: a single technology appraisal.
Hind D; Tappenden P; Peters J; Kenjegalieva K
Health Technol Assess; 2009 Sep; 13 Suppl 2():9-13. PubMed ID: 19804684
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of varenicline for smoking cessation at 2 urban academic health centers.
Dhelaria RK; Friderici J; Wu K; Gupta E; Khan C; Rothberg MB
Eur J Intern Med; 2012 Jul; 23(5):461-4. PubMed ID: 22726377
[TBL] [Abstract][Full Text] [Related]
17. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation.
Lam S; Patel PN
Cardiol Rev; 2007; 15(3):154-61. PubMed ID: 17438382
[TBL] [Abstract][Full Text] [Related]
18. Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates.
Hajek P; McRobbie HJ; Myers KE; Stapleton J; Dhanji AR
Arch Intern Med; 2011 Apr; 171(8):770-7. PubMed ID: 21518946
[TBL] [Abstract][Full Text] [Related]
19. Nicotine dependence and smoking cessation.
Tan L; Tang Q; Hao W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Nov; 34(11):1049-57. PubMed ID: 19952392
[TBL] [Abstract][Full Text] [Related]
20. Nicotine gum dependence treated with varenicline--a case report.
Garelik DA
Nicotine Tob Res; 2010 Oct; 12(10):1041-2. PubMed ID: 20829327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
